(Hyaluronidase (recombinant, human) + immune globulin (human)) is under clinical development by Takeda Pharmaceutical and currently in Phase II for Lymphoma. According to GlobalData, Phase II drugs for Lymphoma have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Hyaluronidase (recombinant, human) + immune globulin (human))’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Hyaluronidase (recombinant, human) + immune globulin (human)) overview
Human normal immunoglobulin with recombinant human hyaluronidase (HyQvia) is an immune sera preparation. It is formulated as injection for subcutaneous route of administration. HyQvia is indicated for the treatment of primary immunodeficiency (PI) in adults and in pediatrics. HyQvia is also indicated for symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.
HyQvia is a combination of human immune globulin (IG) and recombinant human hyaluronidase. It is under development for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), lymphoma and multifocal motor neuropathy (MMN), primary immunodeficiencies in pediatric patients in EU, and for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in the U.S. and EU. It was also under development for the treatment of primary immunodeficiencies (PID) in Canada.
Takeda Pharmaceutical overview
Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company, which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of drugs. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder; and its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.
For a complete picture of (Hyaluronidase (recombinant, human) + immune globulin (human))’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
